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OXALIPLATIN INDUCED PULMONARY FIBROSIS:  
A CASE REPORT
Mirjana Pavlović, Robert Šeparović, Tajana Silovski, Ana Tečić Vuger and Andreja Jurić
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SUMMARY – Oxaliplatin is part of the standard chemotherapy regimens for treating colorectal 
carcinoma. Pulmonary fibrosis is a serious but rare side effect of oxaliplatin treatment, which resulted 
in patient death in more than half of the reported cases. The precise pathophysiological mechanism of 
this phenomenon has not been clarified yet. Analysis of the reported cases strongly suggests that 
early diagnosis and immediate corticosteroid treatment are crucial for better prognosis. Here we re-
port a case of pulmonary fibrosis related to the FOLFOX regimen in a patient with early colorectal 
carcinoma.
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Introduction
Oxaliplatin is a third-generation platin derivative 
which is frequently used as part of chemotherapeutic 
regimen for early and advanced colorectal carcinoma. 
Clinical studies suggest that its toxicity profile includes 
mainly peripheral sensory neuropathy, gastrointestinal 
and hematologic toxicity without mentioning pulmo-
nary side effects, so understanding it is based mostly 
on reported cases. Here we report a case of pulmonary 
fibrosis related to FOLFOX usage in a patient with 
early colorectal cancer.
Case Report
A 66-year-old patient underwent left sided hemi-
colectomy for splenic flexure colon cancer and con-
secutively Hartmann operation due to dehiscence of 
the intestinal anastomosis. The patient was referred to 
our hospital to receive complementary treatment. He 
had a smoking history of 20 pack-years, and no history 
of toxic inhalant exposure, hypertension, diabetes mel-
litus or prior pulmonary disease. Considering histo-
pathologic features of the tumor and results of preop-
erative radiological workup, our multidisciplinary team 
decided to start patient treatment with adjuvant oxali-
platin-based FOLFOX regimen every 2 weeks for 6 
months, with oxaliplatin at 85 mg/m2. During the first 
ten cycles of chemotherapy, the patient reported no 
significant side effects (grade I peripheral neuropathy). 
Eleventh cycle of chemotherapy had to be discontin-
ued before completion because the patient developed 
fever (up to 38.5 °C) with increased inflammatory pa-
rameters but without confirmed site of infection, so he 
was discharged with broad spectrum antibiotic thera-
py. At admission to the hospital two weeks later, the 
patient presented with progressive intolerance of phys-
ical activity and dyspnea. Physical examination re-
vealed prolonged expiration with bibasilar inspiratory 
crackles and arterial blood gas analysis on room air 
showed partial respiratory insufficiency with pO2 of 
8.92 kPa, while laboratory findings showed only 
slightly elevated inflammatory parameters. Multi-slice 
computed tomography of the thorax showed mediasti-
nal lymphadenopathy with enlarged precarinal and 
pretracheal lymph nodes, widespread reticular intersti-
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tial pattern with ground-glass opacities, and honey-
combing in posterobasal segments of the lower lobes, 
which implied incipient fibrosis, none described in 
previous findings (Figs. 1 and 2). Based on the results 
of the diagnostic workup performed, the patient was 
diagnosed with interstitial lung disease (ILD) which 
was, considering the course of the disease, most likely 
caused by the use of oxaliplatin. High-dose intrave-
Fig. 1. Computed tomography scan performed after  
6 cycles of adjuvant FOLFOX therapy showing normal 
finding.
Fig. 2. Computed tomography scan performed after  
11 cycles of FOLFOX therapy showing interstitial lung 
disease with signs of incipient pulmonary fibrosis.
Fig. 3. Computed tomography scan performed two 
months after initiation of corticosteroid therapy showing 
regression of pulmonary interstitial infiltrates.
nous corticosteroid therapy was started immediately 
and the patient was transferred to the pulmonary ward. 
Additional diagnostics included heart ultrasound that 
showed pulmonary hypertension of 38-40 mm Hg; 
6-minute walk test showed significant decrease in sat-
uration after exercise; the patient reported severe dys-
pnea during fiberoptic bronchoscopy, so examination 
could not be completed; chest radiogram showed in-
terstitial infiltrates in the left upper lobe, right lower 
lobe and by the inner side of the thoracic wall bilater-
ally. The patient was discharged home after 10 days 
with oral corticosteroid therapy (prednisone 30 mg). 
In the next few weeks, the patient’s condition im-
proved, his computed tomography finding showed re-
gression of pulmonary interstitial infiltrates, and the 
dose of corticosteroid therapy was gradually decreased 
(Fig. 3).
Discussion
The use of oxaliplatin in clinical practice started in 
20001. At the University Hospital for Tumors, we 
started using oxaliplatin 7 years ago and in the last two 
years we treated a total of 168 patients. Oxaliplatin 
was mostly used as part of FOLFOX regimen for met-
astatic colorectal cancer and less frequently in patients 
with early colorectal cancer and patients with advanced 
gastric or pancreatic cancer. The most frequently re-
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ported side effects in phase III clinical trials include 
peripheral sensory neuropathy, hematologic and gas-
trointestinal toxicity, allergic reactions, and fatigue2. 
According to the Croatian Agency for Medicinal 
Products and Medical Devices (HALMED), the most 
reported side effects of oxaliplatin in Croatia were 
those classified as very common and common in prod-
uct safety profile, such as nervous system disorders 
(peripheral sensory neuropathy), gastrointestinal dis-
orders (diarrhea, abdominal pain), vascular disorders 
(increased blood pressure), and skin disorders (rash, 
hyperhidrosis). To date, visual disturbance (blurred vi-
sion) was reported as a rare side effect of oxaliplatin in 
only one patient. The case presented is the first case of 
pulmonary toxicity related to oxaliplatin use ever not-
ed at the University Hospital for Tumors and the only 
case ever reported in Croatia according to the available 
HALMED data. Homma et al. report on the 0.2% in-
cidence of oxaliplatin induced pulmonary toxicity in 
Japan in 2007, which is consistent with the incidence 
reported in product safety profile (pulmonary toxicity 
is graded as a rare side effect that occurs in <1:1000 
and >1:10000 cases)3. A recently published literature 
review has listed 28 cases of pulmonary toxicity related 
to oxaliplatin use in the form of ILD and pulmonary 
fibrosis, and 16 of them resulted in patient death. The 
authors believe that the actual incidence of this side 
effect is probably higher, but milder cases remain un-
recognized or are not being reported enough. Analysis 
of all reported cases showed that the vast majority of 
patients were men older than 60 years, without pre-
existing lung disease (77%, 92.3% and 73%, respec-
tively); 27% of the patients described had pre-existing 
lung disease, 8% were smokers, and 15% of them had 
arterial hypertension; ten patients received oxaliplatin 
in adjuvant setting, and seven of them died from pul-
monary disease4. The exact pathogenesis of FOLFOX-
induced interstitial pneumonia is unknown. It is as-
sumed that oxaliplatin induces secondary depletion of 
glutathione, a molecule that prevents oxidative damage 
to important cellular components in different organs5. 
One case exhibited good response to N-acetylcysteine 
therapy, which is used as a means of glutathione reple-
tion6. Other presumed pathogenetic mechanisms in-
clude cytotoxic and immune mechanisms. The cyto-
toxic mechanism implies direct effect of the drug and/
or its metabolites on lung cell components and is usu-
ally dose-dependent, while the immune mechanisms 
can include type I (anaphylactic reaction) or type IV 
(late allergic reaction) hypersensitivity reactions3,7. It is 
interesting to mention the attempts of treatment with 
imatinib, where imatinib was identified as a potent in-
hibitor of lung fibroblast-myofibroblast transforma-
tion and proliferation, and extracellular matrix produc-
tion through inhibition of platelet-derived growth fac-
tor and transforming growth factor-β signaling. Treat-
ment with imatinib showed benefit in patients with 
interstitial lung disease, systemic sclerosis and mixed 
connective tissue disease, although results of a ran-
domized double-blind, placebo-controlled study in 
119 patients with interstitial lung disease treated with 
imatinib or placebo for 96 weeks showed no difference 
in overall survival and time to disease progression be-
tween groups8-11. Although there is a small number of 
reported cases of oxaliplatin induced ILD and it is dif-
ficult to draw any firm conclusion from the given data, 
comparison of characteristics of survivors and deceased 
patients showed that early diagnosis and early start of 
treatment is crucial for better prognosis. Discontinua-
tion of the culprit agent and systemic corticosteroids 
have been widely accepted as therapy for drug-induced 
ILD, although there are no randomized controlled tri-
als to confirm its effectiveness12.
Pulmonary complications of chemotherapeutics are 
under-recognized and thus under-reported. Early rec-
ognition is of great importance because it allows prompt 
cessation of chemotherapy and initiation of systemic 
corticosteroids, which can significantly improve patient 
outcome. It is particularly important to keep in mind 
the possibility of this severe side effect in patients treat-
ed with oxaliplatin in the adjuvant setting.
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Sažetak
PLUĆNA FIBROZA IZAZVANA OKSALIPLATINOM: PRIKAZ SLUČAJA
M. Pavlović, R. Šeparović, T. Silovski, A. Tečić Vuger i A. Jurić
Oksaliplatin je dio standardnih kemoterapijskih protokola za liječenje kolorektalnog karcinoma. Plućna fibroza je ozbilj-
na, ali rijetka nuspojava primjene oksaliplatina, koja je rezultirala smrću bolesnika u više od polovine prijavljenih slučajeva. 
Točan patofiziološki mehanizam nastanka ove nuspojave još nije u potpunosti razjašnjen. Analiza prijavljenih slučajeva je 
pokazala da su rana dijagnoza i rani početak liječenja kortikosteroidima od ključne važnosti za bolju prognozu. Ovdje prika-
zujemo slučaj plućne fibroze uz primjenu oksaliplatina u bolesnika s ranim kolorektalnim karcinomom.
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